New combo therapy may let some esophageal cancer patients keep their esophagus

This study is for adults with a type of esophageal cancer (squamous cell carcinoma) that can potentially be removed with surgery. The goal is to see if giving a combination of immunotherapy (tislelizumab) and chemotherapy (carboplatin and nab-paclitaxel) before any procedure can shrink the tumor enough so that it can be removed with an endoscope (a thin tube) instead of major surgery. About 60 participants will receive at least two 3-week cycles of the drugs. If the tumor shrinks completely, they may have endoscopic removal to preserve the esophagus. The study will track how many people can avoid major surgery, side effects, and survival over two years.